Probiotec Limited (ASX:PBP): a proven strategy

January 17, 2020


Probiotec Limited (ASX:PBP) is a leading manufacturer, packer and distributor of a range of prescription and over-the-counter pharmaceuticals, medicines and consumer health products.


PBP (the “Group”) is comprised of three businesses, the parent entity Probiotec, and the subsidiaries being South Pack Laboratories (SPL) and Australian Blister Sealing (ABS).


For the past 4 years, the Group has established a new senior management team who have adopted a new strategy to divest and exit non-core operations. Furthermore, capital has been allocated to growing both organically and through acquisitions within the contract manufacturing areas. Since then, the Group has made a turnaround and is growing rapidly. The rise in return on equity from 5.36% to 8.16% in the past four years proves the quality of new senior management.



Business Segment

Probiotec (the parent entity) services a wide range of large multinational companies, including Pfizer, Proctor & Gamble, Johnson & Johnson and Blackmores. Key customer contracts usually run for 3-5 year terms. In the past 5 years, Probiotec achieved a strong historical contract roll-over rate with no major contracts losses. As a result, Probiotec organically grew at a rate of 20% in FY19.





The Group acquired SPL in FY18 and ABS in FY19, both were acquired at 4-5x EBITDA. The acquisitions increased the Group’s manufacturing capabilities and scales. More importantly, the Group has continued finding attractive acquisitions after the above two. Recently, the Group announced an acquisition of assets from Contract Pharmaceutical Services of Australia Pty Ltd (CPSA). The acquisition is priced at 2x EBITDA, which is extremely inexpensive in the current low-rate environment.



Valuation and Investment Rationale


The company has a strong relationship with customers and is experiencing growth both organically and through acquisition, which in turn represents a 20%+ underlying EBITDA growth rate for the next two years. This gives us an attractive valuation multiple, coupled with the high-quality management team, we believe that the company can continue its growth journey in the long term. At the same time, the Group provides some defensive elements to our portfolio as it operates in the consumer health and medical industry, which is uncorrelated to the general economy. Our valuation for PBP is $3.2.












Share on Facebook
Share on Twitter
Please reload

A winner from the 2020 Federal Budget

October 23, 2020

Themes we like: Software Tech

October 16, 2020

Themes we like: Online Retailers

October 9, 2020

Please reload

Any information has been prepared for the purpose of providing general information only, without taking account of any particular investor's objectives., financial situation or needs, It is not an offer or invitation for subscription or purchase, or a recommendation of any financial product and it is not to be relied on by investors in making an investment decision. Past performance is not a reliable indicator of future performance. To the extent any general financial product advice is provided in this document, it is provided by Glennon Capital Pty Ltd ACN 137 219 866, AFSL No. 338 567. An investor, before acting on anything construed as advice, should consider the appropriateness of such construction and advice having regard to their objectives, financial situation or needs.


Phone: (02) 8027 1000


PO Box R281,

Royal Exchange

NSW, 1225


Level 17

25 Bligh Street

Sydney NSW 2000

(c) 2018 Glennon Capital. All rights reserved.